XUANZHUBIO-B (02575) saw its shares rise more than 12% during the morning trading session. As of the time of writing, the stock was up 12.24%, trading at HK$34, with a turnover of HK$6.5058 million.

The surge follows the recent release of the group's annual results for the period ending December 31, 2025. The company reported revenue of RMB51.772 million, a year-on-year increase of 72.03%. Gross profit reached RMB33.369 million, surging 102.33% compared to the previous year. The loss attributable to owners of the parent narrowed by 55.88% to RMB246 million, while the loss per share was RMB0.53.

During the reporting period, the group implemented flexible and targeted commercial strategies to maximize the advantages of each launched product and target market, achieving notable results. By the end of the period, for the commercialization of its digestive system disease drug Anjiowei®, the group adopted a distribution model combining provincial agents with refined investment recruitment. It established a cumulative internal sales team of 48 members and built a sales network covering over 90 distributors, extending to more than 2,000 medical institutions nationwide.

For the commercialization of its oncology drugs XUANYUENING® and XUANFEINING®, the group pursued a direct sales strategy driven by both market and medical efforts. It formed a specialized commercial team of over 150 members, steadily advancing the domestic commercialization process of its launched products.